Tempus
Tempus is a precision medicine company listed on NASDAQ as TEM and based in Chicago, whose core business is molecular laboratory testing. This record covers its software for clinicians. Next reads unstructured record data to find patients who have not received guideline directed care, starting with biomarker testing in oncology, and surfaces them to physicians and precision medicine teams; a prospective study of 662 lung cancer patients in six community health systems, presented at ASCO 2026, reported higher biomarker testing rates. Hub is the physician platform for ordering Tempus tests and receiving results. Tempus One in EHR (David) is a generative AI assistant inside the electronic health record, with Northwestern Medicine announced as a deployment, and nP Notetaker drafts documentation from encounter audio. Tempus acquired Deep 6 AI in 2025 for trial matching from record data, and in the same year acquired Ambry Genetics, a hereditary and exome testing laboratory that still sells under its own name and is indexed separately. It also acquired Paige, the computational pathology company, in August 2025; Paige still sells under its own name and is indexed separately. Tempus holds FDA clearances for separate electrocardiogram AI products.
The Software Terms of Use set out when Tempus acts as a covered entity (Hub) and when as a business associate (nP Notetaker and Tempus One), with business associate terms and a subcontractor flow down in the same document. The same terms describe the software as research use only and not for informing patient care, provide AI outputs as is, and require the customer to review every output before use. No price, security attestation, model provider or error rate for Next is published. Ask how Next's clinical use squares with the research use wording, and for Tempus's own security attestations.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
The core modules run on models, and the platform carries value beyond them. Next reads unstructured record data to find patients who have not received guideline directed care, such as biomarker testing, and surfaces them to physicians and precision medicine teams; that capability does not exist without the model. Tempus One in EHR (David) is a generative AI assistant inside the record, and nP Notetaker drafts documentation from encounter audio.
Hub, the physician platform for ordering Tempus tests and receiving results, carries value without AI, and the company's laboratory testing business sits around all of it. Remove the models and an ordering platform and a laboratory remain.
Oversight is placed on the customer as a contract term, without a mechanism. The Software Terms of Use require the customer to ensure every AI output is reviewed by a person for accuracy and appropriateness before any use, and bar relying solely on AI output for clinical decisions; they also offer AI agents without stating what those agents may do on their own. Next surfaces patients to physicians and precision medicine teams, who decide what to do. What is not published is any threshold, escalation path or product control that enforces the review the terms require.
The architecture is described in general terms with nothing identified. Next analyzes unstructured record data in near real time, Tempus One in EHR is a generative AI assistant, and the terms describe AI agents; no model, model family, version or update practice is named for any of them on the Next page or in the terms. Tempus publishes research on other models, such as its pathology foundation model, which does not describe these products.
The architecture is described and no model provider is named. The Software Terms of Use bind vendors that handle protected health information to flow down business associate agreements without naming them, and the policy center says data sits in Tempus's secure cloud environments without naming the host. No subprocessor list is published, and the model behind Tempus One in EHR and Tempus's AI agents is not named. Tempus reports building its pathology foundation model with Microsoft, which is outside these products.
Prospective, multi site evidence exists for Next, short of a peer reviewed paper. A study of 662 patients with early stage non small cell lung cancer across six US community health systems, presented at the ASCO 2026 Annual Meeting (abstract 263850) and described in Tempus's 28 May 2026 release, reported ALK testing up 24 percent, EGFR testing up 18 percent and PD-L1 testing up 13 percent within 90 days, and 89 percent of treated patients receiving guideline concordant therapy. The release names none of the health systems, and an abstract carries less method than a full paper. That fits published research short of independent validation.
The published practice is a broad grant over de identified data. The Software Terms of Use let Tempus make and keep a de identified copy of health information received or generated through nP Notetaker, own that copy, and use and share it for any purpose the law permits, and let it use product telemetry to improve its services; the policy center describes a de identification process designed to meet and exceed the HIPAA standard, encryption in transit and at rest, and a form for third party use of de identified data.
Precise wording does not change what the grant permits, which is use and sharing of customer data. Retention periods are not stated, and nothing says whether identifiable data from Next or Tempus One reaches a model provider. The terms warn that AI outputs may hallucinate and are provided as is; no safety engineering is published, meaning no guardrails and no account of how a safety event is handled.
All four elements are published. The Software Terms of Use (last modified 1 December 2025) state that Tempus is a covered entity, and operates as one, when a clinician uses Hub to order Tempus tests and receive results; they state that Tempus performs as a business associate for nP Notetaker and Tempus One in EHR, where the business associate agreement terms set out in the same document apply; and they state that any vendor handling that information is bound by a flow down business associate agreement consistent with those terms. A Notice of Privacy Practices is published in the policy center. The tier is therefore clear by service rather than by price plan.
Controls are asserted with nothing independent behind them. The policy center says data is encrypted in transit and at rest in secure cloud environments, and publishes a responsible disclosure page. Its Information Security Requirements page (last modified April 2022) sets obligations for Tempus's service providers, including a SOC 2 Type 2 report or an audit right, and penetration testing by the provider; those are requirements Tempus places on its suppliers, not an attestation of its own operations. No SOC 2, HITRUST or ISO/IEC 27001 attestation for Tempus itself, and no trust center, appears in the policy center.
A stated position sits in tension with how the lead product is sold. The Software Terms of Use (1 December 2025) say the software is "not cleared or approved or authorized by the FDA, and it is intended solely for research use, not for use in informing or determining patient care"; Hub carries the same wording, and no service specific terms for Next say otherwise.
The Next page markets the product to "identify the next guideline-based step in the care journey" and to prompt testing a physician then orders, which is informing care, with the physician deciding. Tempus separately holds FDA clearances for electrocardiogram AI products, such as its electrocardiogram product for mitral regurgitation, which cover those products and not Next or Tempus One.
Responsible AI appears as oversight language with no evaluation behind it. The Software Terms of Use warn that AI outputs may be inaccurate or hallucinate and require a person to review each output before use, and a January 2026 article on the company's content hub describes a human in the loop framework for its AI assisted data abstraction.
A 2023 blog by the company's chief of AI asks how AI tools can be kept free of bias across patient populations, and no answer for Tempus's own products follows. The policy center, the FAQ, the publications library, the AI articles on the content hub and the Next page carry no responsible AI statement, bias assessment or subgroup results.
This matters for Next in particular: a model finding care gaps in record text can miss patients whose records are thinner or written differently, and no result by group, site type or record system is published.
What is published about a wrong output is its disclaimer. The Software Terms of Use provide AI agents and AI outputs as is and with all faults, warn that outputs may be inaccurate or hallucinate, state that Tempus is not responsible for any use of an AI agent or output, make the customer responsible for review before use, disclaim all warranties, and cap Tempus's liability for direct damages.
No error rate for Next's care gap findings, no correction route for the affected patient, and no remediation obligation is published. A patient's right to amend their record under the Notice of Privacy Practices reaches Tempus's laboratory records, not these software outputs.
A named deployment inside the record, without the record systems named. Tempus One in EHR (David) runs inside the electronic health record, with Northwestern Medicine as the deployment Tempus has announced, and Next reads unstructured record data and delivers alerts into clinical workflow. The Next page says workflows are integrated directly into clinical systems and names no record system, standard or marketplace listing.
A single hosted service with its location implied. The software runs as Tempus hosted applications, and the policy center says data is stored encrypted in Tempus's secure cloud environments, without naming the provider or the region. Nothing commits where identifiable data is processed, and the de identified data Tempus keeps may be shared with third parties, with no border stated.
No price is published for the software, and the posture is discoverable. Next, Hub and Tempus One are sold to health systems and practices under enterprise agreements, and the Software Terms of Use set out how each service is licensed without a figure. Tempus is listed on NASDAQ, so its filings report revenue by segment and describe its dependence on licensing de identified data, which tells a buyer how the company earns money in aggregate and not what a health system will pay.
Coverage is named with validation behind part of it. Next is sold for oncology care gaps, starting with guideline directed biomarker testing, and Tempus also offers cardiology care gap and care pathway solutions; the prospective study behind Next covers early stage lung cancer in six US community health systems. Tempus One in EHR and nP Notetaker are sold to clinicians more broadly. Validation outside lung cancer, and in academic, rural or non US settings, is not published.
Product updates
Material product, regulatory, evidence and commercial changes at Tempus, each verified against a live source and tagged to the capability axis it bears on. Funding rounds and awards are not product changes and are not logged.
Tempus received FDA 510(k) clearance for Tempus ECG-MR, software that reads a standard resting 12 lead ECG and flags signs of moderate or severe mitral regurgitation. It is cleared for adults 65 and older with cardiovascular risk factors and no prior mitral valve diagnosis or intervention, and it returns a binary result meant to prompt referral for imaging, not to diagnose. It is the fourth FDA cleared Tempus ECG AI product.
Tempus received FDA 510(k) clearance for Tempus ECG PH, software that reads a standard 12 lead electrocardiogram and identifies signs associated with pulmonary hypertension. The device does not require new hardware or a new test, since it runs against ECGs that are already being captured for other reasons. This adds to the cleared cardiovascular algorithm suite Tempus has been assembling, and pulmonary hypertension is a deliberate target because it is characteristically diagnosed late.
Tempus announced the publication of a study in Nature Medicine demonstrating the performance of PRISM2, its multimodal slide-level pathology foundation model developed with Microsoft. The model processes routine hematoxylin and eosin slides to predict biomarker status and patient prognosis without requiring specialized fine-tuning.
Alternatives to Tempus
Vendors in the same categories as Tempus whose graded profiles look most alike, with a line on what each product does.
Similar is not the same, so check that each one does the job you need. No vendor pays for placement.
Nest Genomics, the trading name of Nest Health Inc. and a Y Combinator company, sells a genomic care platform that runs inside the electronic health record.
Clinical pathway authoring and governance platform that turns a health system's guidelines, protocols and policies into structured, visual decision logic delivered inside the EHR.
Clinician copilot that ingests data across the EHR, health information exchanges, insurance claims, and care gap files, then uses proprietary language models to classify documents and…
RhythmX AI sells a precision care platform for primary care.
Azra AI reads pathology and radiology reports as they land in the record and turns what it finds into work someone is accountable for.
Birth Model applies machine learning to labor and delivery, and the product has two halves a buyer should assess separately.
Ordered by how closely the graded profiles match across the fifteen axes, inside the same categories. See how each axis is graded in the methodology.
Compared With
Each comparison carries a written verdict, the buyer conditions that favor each vendor, and a graded side by side. Pairs that cross a category boundary are grouped separately, and their verdicts state where the boundary sits rather than manufacturing a head to head.
Announced Deployments
Publicly announced health system deployments and partnerships. This is a record of announcements, not an assessment of deployment success or scale.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise and health system contracts for provider software | Business associate terms are part of the Software Terms of Use and apply to nP Notetaker and Tempus One in EHR, with a flow down to vendors; Tempus acts as a covered entity when Hub is used to order tests and receive results. | Not published. | Vendor Published |
Tempus provider software (Next, Hub, Tempus One in EHR and nP Notetaker) is sold through enterprise and health system agreements; no rate card is published. Tempus is a public company (NASDAQ: TEM), so segment level economics appear in filings, but product pricing does not.
Two things to settle. The unit of charge for each product, and whether Next is priced per patient screened, per site or per program. And what the agreement grants over de identified data, since the Software Terms of Use let Tempus keep and use a de identified copy of data from nP Notetaker.